PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast - Philip J. Mease, MD, MACR - IL-17 Inhibitors in Nonradiographic Axial Spondyloarthritis: Expert Insight on Clinical Decision-Making in an Expanding Therapeutic Landscape

Philip J. Mease, MD, MACR - IL-17 Inhibitors in Nonradiographic Axial Spondyloarthritis: Expert Insight on Clinical Decision-Making in an Expanding Therapeutic Landscape

04/05/21 • 35 min

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Go online to PeerView.com/HYU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in rheumatology discusses treatment with IL-17 inhibitors in nonradiographic axial spondyloarthritis. Upon completion of this activity, participants should be better able to: Recognize unmet needs in the treatment of nonradiographic axial spondyloarthritis (nr-axSpA), Discuss the rationale for IL-17 inhibition as a treatment approach to axSpA, Summarize efficacy and safety data related to IL-17 inhibitors for the treatment of nr-axSpA, Apply anti-IL-17 therapy for the treatment of nr-axSpA in accordance with current evidence and individual patient needs.

Previous Episode

undefined - Robert Dreicer, MD, MS, MACP, FASCO - Making the Right Moves in the Evolving Prostate Cancer Therapeutic Landscape: Expert Guidance on Treatment Sequencing and Selection for Effective Management Across the Disease Continuum

Robert Dreicer, MD, MS, MACP, FASCO - Making the Right Moves in the Evolving Prostate Cancer Therapeutic Landscape: Expert Guidance on Treatment Sequencing and Selection for Effective Management Across the Disease Continuum

Go online to PeerView.com/BCF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. A new, expert-led MasterClass from PeerView and the Us TOO International Prostate Cancer Education & Support Network will provide guidance on individualizing treatment regimens for patients with prostate cancer and will address the latest clinical evidence and guidelines/expert consensus recommendations. The program will also offer information on relevant patient-, tumor-, and treatment-related factors, as well as how to handle patients’ specific needs and preferences. Upon completion of this activity, participants should be better able to: Review recent safety and efficacy data of emerging and available agents across the prostate cancer disease continuum (nmCRPC, mCSPC, mCRPC), including the latest evidence and expert recommendations for selection and sequencing of approved hormonal and chemotherapy options, Outline the latest clinical evidence for appropriate use of novel therapies (eg, PARP inhibitors and immunotherapy) in mCRPC, including monotherapy and combination approaches, Evaluate the latest genetic testing guidelines to better direct treatment decision-making throughout the prostate cancer disease continuum, Develop evidence-based, tailored treatment plans, including the option of clinical trial enrollment, for patients with prostate cancer, based on disease-, patient-, and treatment-specific factors.

Next Episode

undefined - Professor Thomas Powles, MBBS, MRCP, MD - Examining the State of the Science on New Therapies in Bladder Cancer: Perspectives on the Latest Developments Across the Disease Continuum

Professor Thomas Powles, MBBS, MRCP, MD - Examining the State of the Science on New Therapies in Bladder Cancer: Perspectives on the Latest Developments Across the Disease Continuum

Go online to PeerView.com/ECU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology discuss real-world applications of emerging data and innovative therapeutics, offering practical strategies for developing sound, evidence-based protocols to provide more potent and effective treatment options to patients with bladder cancer. Upon completion of this activity, participants should be better able to: Describe when and how novel therapeutic agents in advanced bladder cancer can be used over multiple lines of treatment and across patient populations, Cite the latest safety and efficacy data on newer therapies, including immune checkpoint inhibitors, targeted agents, antibody-drug conjugates and gene therapy across the spectrum of bladder cancer settings, Select novel therapeutics for the management of bladder cancer based on patient-related factors and preferences, Develop appropriate management plans that take into account unique adverse events associated with new immune-, targeted-, and antibody-, and gene therapy-based treatments for bladder cancer.